Literature DB >> 35304666

A Case of XIAP Deficiency Successfully Managed with Tadekinig Alfa (rhIL-18BP).

Ashley V Geerlinks1, Andrea M Dvorak2.   

Abstract

Entities:  

Keywords:  IL-18; Immune dysregulation; Tadekinig alfa; XIAP deficiency

Mesh：

Substances：

Year:  2022        PMID： 35304666     DOI： 10.1007/s10875-022-01236-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.542


× No keyword cloud information.
  1 in total

1.  Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Authors:  Cem Gabay; Bruno Fautrel; Jürgen Rech; François Spertini; Eugen Feist; Ina Kötter; Eric Hachulla; Jacques Morel; Thierry Schaeverbeke; Mohamed A Hamidou; Thierry Martin; Bernhard Hellmich; Peter Lamprecht; Hendrik Schulze-Koops; Delphine Sophie Courvoisier; Andrew Sleight; Eduardo Jorge Schiffrin
Journal:  Ann Rheum Dis       Date:  2018-02-22       Impact factor: 19.103
  1 in total
  2 in total

Review 1.  Immune-mediated inflammatory diseases with chronic excess of serum interleukin-18.

Authors:  Hanae Miyazawa; Taizo Wada
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 2.  Pathogenic roles and diagnostic utility of interleukin-18 in autoinflammatory diseases.

Authors:  Masaki Shimizu; Syuji Takei; Masaaki Mori; Akihiro Yachie
Journal:  Front Immunol       Date:  2022-09-22       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.